Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHNNASDAQ:APRENASDAQ:KNSANASDAQ:RYTMNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AAPREAprea Therapeutics$1.73-0.6%$1.74$1.41▼$5.01$9.62M1.1926,234 shs24,480 shsKNSAKiniksa Pharmaceuticals International$27.95+0.3%$27.62$17.82▼$30.69$2.03B0.05552,656 shs728,425 shsRYTMRhythm Pharmaceuticals$66.39+0.9%$62.90$40.61▼$69.89$4.18B2.26556,938 shs821,801 shsSTOKStoke Therapeutics$11.69+1.8%$10.47$5.35▼$16.15$626.77M1.14672,338 shs534,606 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%APREAprea Therapeutics-1.14%+2.37%-1.14%+5.58%-55.41%KNSAKiniksa Pharmaceuticals International+0.34%+1.01%-7.54%+43.48%+44.37%RYTMRhythm Pharmaceuticals+0.94%+5.06%-2.53%+15.00%+57.02%STOKStoke Therapeutics+1.78%+3.00%+4.94%+98.14%-10.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPREAprea Therapeutics2.4811 of 5 stars3.54.00.00.00.00.81.3KNSAKiniksa Pharmaceuticals International3.3992 of 5 stars3.54.00.00.02.03.30.6RYTMRhythm Pharmaceuticals3.3333 of 5 stars2.52.00.04.32.00.80.6STOKStoke Therapeutics3.9941 of 5 stars3.60.00.04.82.30.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHNAchillion Pharmaceuticals 0.00N/AN/AN/AAPREAprea Therapeutics 3.00Buy$15.50795.95% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8038.82% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$78.0717.60% UpsideSTOKStoke Therapeutics 3.29Buy$23.2098.46% UpsideCurrent Analyst Ratings BreakdownLatest RYTM, APRE, KNSA, ACHN, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$88.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.006/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.005/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/7/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHNAchillion PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AAPREAprea Therapeutics$1.50M6.38N/AN/A$3.55 per share0.49KNSAKiniksa Pharmaceuticals International$423.24M4.82N/AN/A$6.60 per share4.23RYTMRhythm Pharmaceuticals$130.13M32.46N/AN/A$0.35 per share189.69STOKStoke Therapeutics$36.56M17.46N/AN/A$4.32 per share2.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHNAchillion Pharmaceuticals-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/AAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A111.80N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.7914.80N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest RYTM, APRE, KNSA, ACHN, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A8/5/2025Q2 2025STOKStoke Therapeutics-$0.0905N/AN/AN/A$31.51 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHNAchillion Pharmaceuticals0.018.968.96APREAprea TherapeuticsN/A5.905.90KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43RYTMRhythm PharmaceuticalsN/A3.303.13STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHNAchillion Pharmaceuticals79.42%APREAprea Therapeutics34.19%KNSAKiniksa Pharmaceuticals International53.95%RYTMRhythm PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipACHNAchillion Pharmaceuticals4.58%APREAprea Therapeutics13.63%KNSAKiniksa Pharmaceuticals International53.48%RYTMRhythm Pharmaceuticals6.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHNAchillion Pharmaceuticals56140.05 millionN/AOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableRYTM, APRE, KNSA, ACHN, and STOK HeadlinesRecent News About These CompaniesStoke City move early for 'lethal' rising Manchester City star in second signing of the dayJuly 7 at 4:49 AM | msn.comNew Hanford waste incinerator could keep patients warm at Royal StokeJuly 7 at 4:49 AM | msn.comStoke sign Talovierov and Man City's MubamaJuly 7 at 4:49 AM | msn.comZebra crossings to be installed outside TWO schools on same Stoke-on-Trent roadJuly 5 at 11:14 PM | msn.comStoke-on-Trent-based Prohire Limited falls into administrationJuly 5 at 11:14 PM | bbc.co.ukMaksym Talovierov makes 'cold nights' promise with brilliant Stoke City statementJuly 5 at 11:14 PM | msn.comDONE DEAL: Stoke snap up Man City striker MubamaJuly 5 at 11:14 PM | tribalfootball.comTFive Guys to open first Stoke-on-Trent restaurantJuly 5 at 11:14 PM | msn.comMubama set for Stoke loan switchJuly 5 at 11:14 PM | sports.yahoo.comPorch pirates target Stoke-on-Trent as parcels swiped from doorstepsJuly 3, 2025 | uk.news.yahoo.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $23.20 Average Target Price from BrokeragesJuly 3, 2025 | americanbankingnews.comStoke City on brink of agreement for Plymouth Argyle record signingJuly 2, 2025 | msn.comStockley named Stoke's new academy managerJuly 2, 2025 | msn.comStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCJuly 1, 2025 | marketbeat.comMichelin’s Stoke-on-Trent plant set to lower CO2 emissions with tyre reprocessing siteJuly 1, 2025 | thebusinessdesk.comTStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from AnalystsJune 30, 2025 | marketbeat.comSTOK Stoke Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)June 28, 2025 | theglobeandmail.comStoke-on-Trent bungalow could be turned into children's homeJune 28, 2025 | msn.comStoke City confirm new coach appointment as pre-season startsJune 27, 2025 | msn.comTraditional Stoke-on-Trent pub reopens for the first time since CovidJune 27, 2025 | stokesentinel.co.ukSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYTM, APRE, KNSA, ACHN, and STOK Company DescriptionsAchillion Pharmaceuticals NASDAQ:ACHNAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Aprea Therapeutics NASDAQ:APRE$1.73 -0.01 (-0.57%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.74 +0.01 (+0.58%) As of 07/7/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiniksa Pharmaceuticals International NASDAQ:KNSA$27.95 +0.07 (+0.25%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$27.62 -0.33 (-1.18%) As of 07/7/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Rhythm Pharmaceuticals NASDAQ:RYTM$66.39 +0.62 (+0.94%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$65.86 -0.53 (-0.80%) As of 07/7/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$11.69 +0.21 (+1.83%) As of 07/7/2025 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
